FDA Gives AI Cervical Slide Readers a Regulatory Category
Published Date: 11/5/2026
Rule
Summary
The FDA is officially classifying digital cervical cytology slide imaging systems with AI as class II devices, meaning they have special safety rules but fewer regulatory hurdles. This change helps make these smart medical tools safer and easier to get to patients, starting November 5, 2026, with the classification effective retroactively from January 31, 2024. Labs and device makers will benefit from clearer rules and faster access to innovative tech without extra costs.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
New Testing, Labeling, and 510(k) Requirements
If you develop or market these systems, they are prescription in vitro diagnostic devices and are subject to premarket notification under section 510(k). You must meet the final order's special controls, including detailed labeling (intended use, patient population, training), extensive design verification and validation across hardware and software components, clinical validation showing non-inferiority to an appropriate comparator, intended user screening time data, and human factors studies. The order is effective November 5, 2026 and the classification was applicable January 31, 2024.
AI Pap Test Systems Reach Patients Faster
You may get earlier access to AI-assisted Pap test slide imaging because the FDA classified these systems as Class II (special controls), with the order effective November 5, 2026 and the classification applicable January 31, 2024. The FDA says this reclassification will enhance patients' access to beneficial innovation by reducing regulatory burdens.
Easier 510(k) Path for Future Devices
If you make these devices, the De Novo classification means this device type can serve as a predicate for future devices, allowing sponsors to use the less-burdensome 510(k) premarket notification process instead of premarket approval. The FDA issued the De Novo order January 31, 2024 and codified the classification effective November 5, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-22590, Medical Devices; Neurological Devices; Classification of the Prognostic Assessment Software of Mild Cognitive Impairment
The FDA is officially putting mild cognitive impairment prognostic software into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to these helpful tools faster and ensures the devices are safe and effective. The new rules took effect November 5, 2026, but have been in place since January 11, 2024, giving companies clear guidance on what’s expected.
Next: 2026-22600, Modernizing Spectrum Sharing for Satellite Broadband
The FCC is updating the rules for how geostationary satellites share the airwaves to make sure satellite internet works better and more fairly. These changes affect satellite companies and will take effect on December 7, 2026. No extra paperwork or big costs are expected, just smoother satellite broadband for everyone.